1. Introduction
===============

Open gastrectomy is a frequent surgery performed due to the high morbidity of gastric diseases in our country. Inevitably, the incision made in the abdominal wall contributes to severe postoperative pain which may cause decreased function of immune system, decreased healing, and painful suffering; these changes may probably negatively affect the postoperative recovery quality.^\[[@R1],[@R2]\]^

Successful postoperative analgesia facilitates faster recovery, improves patient satisfaction. Traditionally, the most frequently used analgesic method for abdominal surgery is patient-controlled intravenous analgesia (PCIA), the main drug used is opioids. However, opioid-induced side effects such as nausea or vomiting, pruritus (itching), urinary retention, sedation, and respiratory depression are very common.^\[[@R3],[@R4]\]^ In order to reduce opioid-related adverse effects, a multimodal postoperative analgesia is recommended.

As a component of multimodal postoperative pain management, infiltration with local anesthetic around the surgical wound is an effective analgesic technique, which could decrease postoperative wound pain and analgesic usage.^\[[@R5]\]^ Unfortunately, the analgesia duration of local anesthetics is limited, peripheral nerve catheter is 1 method to provide prolonged or continuous analgesia for various peripheral regional anesthetic techniques. However, there are still some disadvantages of this method, such as dislocation of catheters^\[[@R6]\]^ or catheter infection.^\[[@R7]\]^ Thus an adjuvant which could extend the duration of single-shot peripheral nerve block is of particular interest. Undoubtedly, dexmedetomidine (DEX) is an ideal adjuvant in this context.

DEX is a strong and highly selective α2-adrenoceptor agonist. It could enhance the analgesic efficacy of local anesthetics when added as an adjuvant for peripheral regional nerve block.^\[[@R8]--[@R10]\]^

Therefore, we hypothesized that adding DEX to ropivacaine for wound infiltration could enhance the analgesic efficacy of ropivacaine. Therefore, we designed a prospective, double-blinded, randomized study to assess the effect of DEX as an adjuvant to ropivacaine for wound infiltration in patients undergoing open gastrectomy.

2. Materials and methods
========================

2.1. Patients
-------------

The study was approved by the Hospital Ethics Committee of the Lianyungang clinical college of Nanjing medical university. After obtaining written information consent from patients, 50 patients aged 35 to 75 years with American Society of Anesthesiologists (ASA) grade I to III and underwent open gastrectomy in our hospital were enrolled. Patients were excluded if they had a history of allergy to any local anesthetics, body mass index \>30 kg/m^2^, opioids addiction or abuse, chronic pain, and psychiatric diseases which would affect postoperative assessments.

2.2. Randomization and study design
-----------------------------------

Randomization into 1 of the 2 groups was based on computer random number generation. The randomization sequence was generated by a statistician who was not involved in the study. The details of the series were unknown to both the investigators and the patients, and the group assignments were kept in sealed envelops. After the patient entering into the operation room and just before the induction of anesthesia, the numbered envelope was opened and the card inside determined into which group the patient would be placed.

Patients were randomized to receive ropivacaine wound infiltration (group R) or ropivacaine with DEX (group RD). In group R, wound infiltration initiated with 20 mL 0.3% ropivacaine (batch 14111736; Hengrui Medicine, Jiangsu, China) plus 2 mL normal saline. In group RD, wound infiltration initiated with 20 mL 0.3% ropivacaine plus 2 mL 1.0 μg/kg DEX (batch 13070534; Hengrui Medicine) dissolved in normal saline.

The patients, the surgeon, the anesthesiologists, and the staff who collect the data were all blinded to the study drugs or the patient\'s group assignment.

2.3. Procedure of anesthesia and wound infiltration
---------------------------------------------------

After arriving at the operation room, all the patients received standard examinations including electrocardiogram, pulse oxygen saturation (SpO~2~), invasive blood pressure, and bispectral index (BIS) monitoring. All patients in both groups received the same anesthetic protocol. Patients received propofol 2 mg/kg, sufentanil 0.5 μg/kg, and cisatracurium 0.15 mg/kg for induction. After tracheal intubation, mechanical ventilation was conducted with a tidal volume of 6 to 8 mL/kg and P~ET~CO~2~ of 35 to 45 mm Hg. Anesthesia was maintained with sevoflurane/O~2~/air mixture to keep BIS values between 40 and 60, cisatracurium was injected intravenously for muscle relaxation. Before the incision was sutured, ropivacaine or ropivacaine with DEX were infiltrated into the tissues around the incision, including the peritoneum, muscles, and subcutaneous tissue. All the surgical interventions were performed by the same surgical team.

2.4. Postoperative pain management
----------------------------------

After operation, patients in both groups received a sufentanil-based intravenous patient-controlled analgesia (PCA) pump (total 2 μg/kg sufentanil in 100 mL saline with 1 pump press delivering a 1.5 mL bolus and a continuous background infusion of 0.04 μg/kg/h sufentanil). If the visual analogue scale (VAS) pain score assessed was \>4, 3 μg sufentanil as rescue analgesia was injected intravenously. Considering the strong analgesic efficacy of sufentanil, other analgesics were not administered.

2.5. Studied variables
----------------------

Patient demographic information including age, weight, sex, ASA class, surgical approach, and time of operation were recorded.

VAS (0--10) pain score (VAS; 0, no pain, to 10, worst possible pain) was measured at 2, 4, 6, 8, 10, 12, and 24 hours time points after the end of surgery.

PCA press number and sufentanil consumption (PCA infused plus rescued sufentanil) were recorded at 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, and 10 to 12 hours time intervals, and the total amount of 24 hours sufentanil consumption was also recorded in both groups.

Incidence of postoperative nausea and vomiting (PONV) for the first 24 hours after the end of surgery, and wound healing score (1, no effusion, 2, effusion, 3, infection) for the first 72 hours after the end of surgery were also analyzed.

Primary outcome measure in this study was the 24 hours sufentanil consumption. The secondary outcome measures included VAS pain score, PCA pump press number, incidence of PONV, and wound healing score.

2.6. Statistical analysis
-------------------------

According to our pilot study, a power analysis was performed using the 24 hours total sufentanil consumption. We projected a mean 24 hours sufentanil consumption of 92.1 ± 20.9 in 10 patients who received wound infiltration with ropivacaine. We calculate that 20 patients were required for each group to detect significant between-group differences of 20%, with an α = 0.05, 2-tailed and β = 0.2. Taking into account potential dropouts in both groups, we decided to enroll 50 patients.

Statistical analyses were performed using SPSS 16.0 for windows (SPSS 16, Chicago, IL). Continuous numerical data were expressed as median and interquartile range or mean and standard deviation. Categorical data were expressed as frequencies and percentages. Normally distributed numerical data between groups were analyzed using the Student *t* test. Skewed data between groups were analyzed by the Mann--Whitney *U* test. Categorical variables were compared using the Fisher exact test or the Pearson Chi-square test as applicable. All tests were 2 tailed. *P* \< .05 was considered statistically significant.

3. Results
==========

Fifty patients were enrolled in this study. Four patients were excluded: 3 patients refused to participate in the study and 1 patient was converted to laparoscopic surgery. Of the remaining 46 patients, 23 patients were randomized in each group in this study (Fig. [1](#F1){ref-type="fig"}).

![CONSORT diagram.](medi-96-e7950-g001){#F1}

3.1. Demographic characteristics
--------------------------------

Patients in both groups had comparable demographic characteristic data and surgical approach as well as operation time (*P* \> .05) (Table [1](#T1){ref-type="table"}).

###### 

Comparison of demographics, surgical approach, and operation time between the 2 groups.
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3.2. VAS pain score
-------------------

The postoperative VAS pain score decreased gradually over time in both groups. However, there was no significant difference between the 2 groups during the observation time points (*P* \> .05) (Table [2](#T2){ref-type="table"}).

###### 

Comparison of VAS between the 2 groups.
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3.3. Sufentanil consumption and PCA press number at different time intervals
----------------------------------------------------------------------------

The PCA pump press number in group R was higher than that in group RD at 0 to 2, 2 to 4, 4 to 6-hour time intervals except 6 to 8, 8 to 10, and 10 to 12-hour time intervals. Along with the change of the PCA pump press number, the sufentanil consumption in group R was also higher than that in group RD at the same time intervals (*P* \< .05) (Table [3](#T3){ref-type="table"}).

###### 

Comparison of PCA pump press number and sufentanil consumption between the 2 groups at different time intervals.
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3.4. Postoperative parameters
-----------------------------

Compared with group RD, the total 24 hours sufentanil consumption was higher than that in group R (*P* \< .05). The incidence of PONV for the first 24 hours after the end of surgery in group R was higher than that in group RD; however, there was no significant difference between the 2 groups, the wound healing scores for the first 72 hours after the end of surgery in the 2 groups were comparable (*P* \> .05) (Table [4](#T4){ref-type="table"}).

###### 

Comparison of 24 hours sufentanil consumption, wound healing score, and PONV between the 2 groups.
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4. Discussion
=============

In this prospective study of patients who underwent open gastrectomy, the results indicated that 1.0 μg/kg DEX, as an adjuvant to 0.3% ropivacaine for wound infiltration, enhanced the analgesic effect of ropivacaine, as shown by lower requirement for postoperative sufentanil consumption and fewer PCA pump press number. Meanwhile, adding DEX to ropivacaine did not affect the wound healing.

Patients who underwent open gastrectomy usually complain of severe pain during the postoperative period, which may result in severe postoperative complications, prolong hospital stays, and develop to chronic pain.^\[[@R11]\]^

Successful management of postoperative pain facilitates faster postoperative recovery, improves patient\'s satisfaction, and may shorten hospitalization. Traditionally, PCIA is frequently used as the main component of postoperative pain management after major abdominal surgery. However, the use of opioids in PCIA is often associated with adverse effects, such as PONV, respiratory depression, urine retention, intestinal obstruction, and other side effects.^\[[@R12]\]^ EA could also provide better analgesia than PCIA, but it may be limited in daily clinical application due to contraindications, technical failure, or disastrous complications.^\[[@R13]\]^

Wound infiltration with local anesthetics could be used as an effective supplement component of multimodal postoperative analgesia. Lee et al^\[[@R5]\]^ reported that local anesthesia infiltration at wound site decreased postoperative wound pain and analgesic usage in patient who underwent single-incision laparoscopic colectomy. Kong et al^\[[@R14]\]^ suggested that ropivacaine wound infiltration reduced the opioid analgesic requirement and incidence of PONV, while provided a good analgesia. This technique is beneficial but cannot offer long-term pain control; thus, how to prolong the effect of one single-shot administration of local anesthetics should be under consideration.

DEX is a highly selective and strong α2-adrenoceptor agonist which has sedative, analgesic, and sympatholytic properties. It has gained widespread clinical applications as an adjuvant to local anesthetics for peripheral regional anesthetic techniques.^\[[@R8]--[@R10]\]^ However, there are a few clinical studies regarding DEX added to local anesthetics for wound infiltration. In a recent study, Mandal et al^\[[@R8]\]^ suggested that DEX added to 2% lignocaine with adrenaline for local infiltration at the trauma site not only reduced bleeding but also decreased perioperative fentanyl consumption, and provided better surgeon\'s satisfaction score and lesser side effects. In another study, Kim and Kang^\[[@R15]\]^ reported that adding DEX to ropivacaine for perianal injection may have an additive effect in reducing postoperative pain and fentanyl consumption in patient who underwent hemorrhoidectomy.

In our study, to reduce the patient\'s postoperative pain and improve the patient\'s analgesia, an additional 3 μg sufentanil was injected intravenously as long as the pain the patient complained was higher than a VAS pain score of 4; thus, no significant difference in VAS pain score was observed between the 2 groups. However, we still could come to the conclusion that adding DEX to ropivacaine for wound infiltration promoted the analgesic efficacy of ropivacaine from the decreased PCA pump press number and sufentanil consumption during the first 6 hours after surgery. The efficacy of wound infiltration decreased gradually as time extended, the PCA may play a relatively important role in postoperative analgesic care from 6 to 24 hours after surgery. Meanwhile, the pain the patient complained was also decreased, that might be the reasons no significant differences in PCA pump press number and sufentanil consumption were observed from 6 to 24 hours after surgery.

The exact mechanism of action of DEX is still unknown, but 2 possible theories have been clarified: The first one is vasoconstriction mediated by action of vascular α-2 adrenoceptors around the site of injection, which delays the absorption of local anesthetic and prolongs the efficacy of local anesthetic.^\[[@R16]\]^ Akimoto et al^\[[@R17]\]^ recently reported that DEX improved the tissue distribution and anesthetic action of lidocaine; this effect may be related to vasoconstriction caused by DEX. Masuki et al^\[[@R18]\]^ also reported that DEX could cause more α2-selective vasoconstriction than clonidine in the human forearm. The second one is a direct effect on peripheral nerve activity, which is mediated directly by blocking an activity-dependent cation current (the *I*~h~ current); the *I*~h~ current normally acts to reset the nerve from a hyperpolarized state back to the resting membrane potential.^\[[@R19]\]^ By keeping the nerve in a hyperpolarized state, the nerve is unable to generate a new action potential, especially in C-fibers and Aδ fibers.^\[[@R20]\]^ Thus, the effect of DEX might be associated with vasoconstriction or peripheral nerve activity; however, further studies are still needed to explore the mechanism for the action in detail. In our study, it was possible that DEX interfered with the absorption of ropivacaine via vasoconstriction. Meanwhile, DEX inhibited the impulse conduction in primary afferents by blocking the *I*~h~ current, these effects may contribute to the result that DEX potentiate the analgesic efficacy of ropivacaine for wound infiltration.

The risk of delayed wound healing might be 1 reason that surgeons are hesitate to use the wound infiltration anesthesia technique. However, the result of our study showed that wound healing was not affected by this technique. In addition, the vasoconstriction around the wound mediated by DEX may reduce the effusion from the wound, which might be beneficial to the wound healing.

PONV are common complications concerning patients receiving opioids for PCIA). Intensive research was performed to develop therapeutic strategies to prevent this complication. Many investigators have suggested that DEX could reduce the incidence of PONV. Song et al^\[[@R21]\]^ reported that adding DEX to a fentanyl-based PCA pump reduced the frequency and severity of nausea in patients with at least 3 risk factors for PONV. Mohta et al^\[[@R22]\]^ also reported that DEX added to bupivacaine for paravertebral block decreased the incidence of PONV in patients who underwent major breast cancer surgery. Although the incidence of PONV was decreased in group RD in this study, there was no significant difference between the 2 groups, the sample size was small might be the reason.

5. Limitations
==============

There were still some limitations in this study. First, only 1 concentration of DEX and ropivacaine were evaluated in our study. Additional studies are needed to investigate more concentration of DEX and ropivacaine. Second, we recorded the VAS pain score every 2 hours during the first 12 hours after the surgery, some patients may fall asleep when we assessed the VAS pain score, and this may make the patients uncomfortable. Third, the plasma concentration of DEX was not detected in our study; further studies are needed to explore whether its action was related to systemic absorption.

6. Conclusions
==============

Taken together, wound infiltration is an effective and safe postoperative analgesic technique, which could be as an effective component of multimodal postoperative analgesic regimen; adding 1.0 μg/kg DEX to 0.3% ropivacaine for wound infiltration prompted the analgesic properties of ropivacaine, reduced sufentanil consumption, and had no effect on wound healing; it could be as an ideal adjuvant which potentiates the analgesic efficacy of local anesthetics.

Abbreviations: ASA = American Society of Anesthesiologists, BIS = bispectral index, DEX = dexmedetomidine, DR = dexmedetomidine with ropivacaine, PCA = patient-controlled analgesia, PCIA = patient-controlled intravenous analgesia, PONV = postoperative nausea and vomiting, R = ropivacaine, VAS = visual analogue scale.
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